



CORRECTION **OPEN**

Correction: Systematic review and meta-analysis determining the benefits of in vivo genetic therapy in spinal muscular atrophy rodent models

Ellie M. Chilcott , Evalyne W. Muiruri, Theodore C. Hirst and Rafael J. Yáñez-Muñoz 

© The Author(s) 2022

Gene Therapy (2023) 30:188; <https://doi.org/10.1038/s41434-022-00377-8>

Correction to: *Gene Therapy* (2021) 29:498–512 <https://doi.org/10.1038/s41434-021-00292-4>, published online 06 October 2021

In this article, the title and caption of Table 3 were incorrectly given. They should have been as below.

Table 3. Characteristics of clinical trials using Spinraza and Zolgensma.

Outcome measures reported at set follow-up time points: Chiriboga et al. [75]: 9–14 months, Finkel et al. [77]: up to 32 months, Finkel et al. [78]: day 394, Mercuri et al. [79]: 15 months, Darras et al. [76]: days 253 and 1050, respectively, Mendell et al. [10]: 24 months. HFMSE, HINE-2, and CHOP-INTEND scores represent change from baseline. Finkel et al. [77] define motor milestone response as “improvement of two or more levels per motor milestone category in at least one category”. Finkel et al. [78] define motor milestone response as “improvement in at least one HINE-2 motor milestone with more categories with

improvement than worsening”. Mercuri et al. [79] define motor milestone response as achievement of “≥1 new World Health Organisation motor milestone”.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022